Literature DB >> 21229400

Primary plasma cell leukemia followed by testicular plasmacytoma.

Caterina Giovanna Valentini1, Valentina Bozzoli2, Luana Fianchi2, Maria Teresa Voso2, Gianluigi Di Paolantonio2, Marianna Criscuolo2, Giuseppe Leone2, Luigi Maria Larocca3, Livio Pagano2.   

Abstract

Plasma cell leukemia (PCL) is a highly aggressive plasma cell disease characterized by a poor prognosis and a low response rate to conventional therapy. Herein, we describe a 69-year-old patient with primary PCL, developing testicular disease while in complete hematological remission, following by muscle involvement and peritoneal dissemination.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21229400     DOI： 10.1007/s12185-010-0745-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  18 in total

1.  Relapsed plasma cell leukaemia presenting with aggressive extramedullary plasmacytomas in the meninges and testis--a missed opportunity for induction CNS prophylaxis.

Authors:  Jeremy Wellwood; Kerry Taylor; Susan Wright; Mark Bentley; Geoff Hill; Huong Phan; Debra Norris; Roger Livsey
Journal:  Leuk Lymphoma       Date:  2002-04

2.  Bortezomib is effective in primary plasma cell leukemia.

Authors:  Damian P J Finnegan; Paul Kettle; Mary Drake; Christine Matthews; H Denis Alexander; Rakesh Popat; Jamie D Cavanagh; William Wachsman; T C M Morris
Journal:  Leuk Lymphoma       Date:  2006-08

3.  Secondary testicular plasmocytoma.

Authors:  Miguel Alvarez-Múgica; Antonio Jalón Monzón; Verónica Bulnes Vázquez; Carolina Aguilar Andrea; Jesús M Fernández Gómez; Roberto C González Alvarez; Francisco J Regadera Sejas
Journal:  Arch Esp Urol       Date:  2007 Jan-Feb       Impact factor: 0.436

4.  Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.

Authors:  Chadi Al-Nawakil; Jerome Tamburini; Valerie Bardet; Nicolas Chapuis; Edward Bourry; Christian Roux; Sophie Park; Sylvain Choquet; François Dreyfus; Didier Bouscary
Journal:  Leuk Lymphoma       Date:  2008-10

5.  Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone.

Authors:  J D Walker; R S Kaczmarski
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

Review 6.  Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.

Authors:  D T Alexandrescu; L Koulova; P H Wiernik
Journal:  Clin Exp Dermatol       Date:  2005-07       Impact factor: 3.470

7.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Authors:  C Pellat-Deceunynck; S Barillé; G Jego; D Puthier; N Robillard; D Pineau; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

8.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  Efficacy and safety of bortezomib in patients with plasma cell leukemia.

Authors:  Pellegrino Musto; Fausto Rossini; Francesca Gay; Vincenzo Pitini; Tommasina Guglielmelli; Giovanni D'Arena; Felicetto Ferrara; Nunzio Filardi; Roberto Guariglia; Antonio Palumbo
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

Review 10.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490
View more
  4 in total

1.  Synchronous Thyroid Involvement in Plasma Cell Leukemia Masquerading as Hashimoto's Thyroiditis: Role of Ancillary Cytology Techniques in Diagnostic Workup.

Authors:  Ashwani Tandon; T Roshni Paul; Rekha Singh; A M V R Narendra
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

2.  Plasmacytoma presenting as hematuria.

Authors:  Khurram Abbass; Shabana Dewani; Ronald Markert; Michael K Kaplon; Michael A Baumann
Journal:  Int J Hematol       Date:  2011-05-07       Impact factor: 2.490

3.  Incidental discovery of a testicular plasmacytoma at initial presentation of multiple myeloma.

Authors:  Amanda R Hathaway
Journal:  Case Rep Hematol       Date:  2013-05-07

4.  Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature.

Authors:  Munad Khan; Nieroshan Rajarubendra; Sarah Azer; Alison Skene; Simon J Harrison; Belinda Campbell; Nathan Lawrentschuk
Journal:  Urol Ann       Date:  2015 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.